Frontiers in Microbiology · 2021 · 23 citations · 12 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceHost-pathogen InteractionsMicrobial PathogenesisAntibacterial PharmacologyAntibacterial ResistanceAntibacterial TherapyAntibiotic ResistanceAntimicrobial TherapyCombination Antimicrobial TherapyAntibacterial Drug DevelopmentAntibacterial Drug RepurposingAntimicrobial Drug RepurposingAntimicrobial Resistance In Enteric PathogensEnterococcal InfectionsEnterococciVancomycin-resistant Enterococcal InfectionVancomycin-resistant Enterococci
Widespread antibiotic resistance has been reported in enterococcal pathogens that cause life-threatening infections. Enterococci species rapidly acquire resistance and the pace of new antibiotic development is slow. Drug repurposing is a promising approach in solving this problem. Bithionol (BT) is a clinically approved anthelminthic drug. In this study, we found that BT showed significant antimicrobial and antibiofilm effects against Enterococcus faecalis and vancomycin-resistant Entercococcus faecium in vitro , in a dose-dependent manner, by disrupting the integrity of the bacterial cell membranes. Moreover, BT effectively reduced the bacterial load in mouse organs when combined with conventional antibiotics in a peritonitis infection model. Thus, BT has shown potential as a therapeutic agent against E. faecalis - and vancomycin-resistant E. faecium -related infections.
12
A new antibiotic selectively kills Gram-negative pathogens
Yu Imai, Kirsten J. Meyer, Akira Iinishi et al. · Nature · 2019 · 741 citations · Full text
Emel Mataracı, Sibel Döşler · Antimicrobial Agents and Chemotherapy · 2012 · 256 citations · Full text